GENEVA, Oct. 11, 2021 /PRNewswire/ 18-month results from the PRESTIGE Below-the-Knee (BTK) study have been presented as a Late Breaking Clinical Trial at VIVA21. The objective of this clinical
GENEVA, Oct. 11, 2021 /PRNewswire/ - 18-month results from the PRESTIGE Below-the-Knee (BTK) study have been presented as a Late Breaking Clinical Trial - Report on The Eastern Herald
12-Month Below-the-Knee Data with MedAlliance s SELUTION SLR Presented as Late Breaking Trial at LINC
NYON, Switzerland, Jan. 28, 2021 /PRNewswire/ 12-month results from the PRESTIGE Below-the-Knee (BTK) study have been presented as a Late Breaking Trial at LINC 2021. The objective of this clinical investigation has been to evaluate safety and performance outcomes of SELUTION SLR, MedAlliance s novel sirolimus-eluting balloon, for the treatment of long tibial occlusive lesions (TASC C & D) in patients with Critical Limb Ischemia (CLI).
The Primary Patency Rate was 78% and the rate of wound healing was 81%. Freedom from Target Lesion Revascularization (TLR) was exhibited by 93% of patients and 84% demonstrated Amputation Free Survival (AFS). All these figures have been sustained from the six-month data.